Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M)

Abstract

Background: Advances in HIV-1 therapeutics have led to the development of a range of daily oral treatment regimens, which share similar high efficacy rates. Consequently, more emphasis is being placed upon the individual's experience of treatment and impact on quality of life. The first long-acting injectable antiretroviral therapy for HIV-1 (long-acting cabotegravir + rilpivirine [CAB + RPV LA]) may address challenges associated with oral treatment for HIV-1, such as stigma, pill burden/fatigue, drug-food interactions, and adherence. Patient-reported outcomes (PROs) collected in an HIV-1 clinical trial (ATLAS-2M; NCT03299049) comparing participants' experience with two dosing regimens (every 4 weeks [Q4W] vs. every 8 weeks [Q8W]) of CAB + RPV LA are presented herein.

Methods: PRO endpoints evaluated through 48 weeks of therapy included treatment satisfaction (HIV Treatment Satisfaction Questionnaire [HIVTSQ]), treatment acceptance ("General Acceptance" domain of the Chronic Treatment Acceptance [ACCEPT®] questionnaire), acceptability of injections (Perception of Injection [PIN] questionnaire), treatment preference (questionnaire), and reasons for switching to/continuing long-acting therapy (exploratory endpoint; questionnaire). Participants were randomized 1:1 to receive CAB + RPV LA Q8W or Q4W. Results were stratified by prior CAB + RPV exposure in either preplanned or post hoc analyses.

Results: Overall, 1045 participants were randomized to the Q8W (n = 522) and Q4W (n = 523) regimens; 37% (n = 391/1045) had previously received CAB + RPV in ATLAS. For participants without prior CAB + RPV exposure, large increases from baseline were reported in treatment satisfaction in both long-acting arms (HIVTSQ status version), with Q8W dosing statistically significantly favored at Weeks 24 (p = 0.036) and 48 (p = 0.004). Additionally, improvements from baseline were also observed in the "General Acceptance" domain of the ACCEPT questionnaire in both long-acting arms for participants without prior CAB + RPV exposure; however, no statistically significant difference was observed between arms at either timepoint (Week 24, p = 0.379; Week 48, p = 0.525). Significant improvements (p < 0.001) in the "Acceptance of Injection Site Reactions" domain of the PIN questionnaire were observed from Week 8 to Weeks 24 and 48 in both arms for participants without prior CAB + RPV exposure. Participants with prior CAB + RPV exposure reported high treatment satisfaction (mean [HIVTSQ status version]: Q8W 62.2/66.0; Q4W 62.0/66.0), treatment acceptance (mean: Q8W 89.3/100; Q4W 91.2/100), and acceptance of injection site reactions (mean [5 = not at all acceptable; 1 = totally acceptable]: Q8W 1.72; Q4W 1.59) at baseline/Week 8 that were maintained over time. Participants without prior CAB + RPV exposure who received Q8W dosing preferred this regimen over oral CAB + RPV (98%, n = 300/306). Among those with prior Q4W exposure, 94% (n = 179/191) preferred Q8W dosing versus Q4W dosing (3%, n = 6/191) or oral CAB + RPV (2%, n = 4/191).

Conclusions: Both long-acting regimens provided high treatment satisfaction and acceptance, irrespective of prior CAB + RPV exposure, with most participants preferring Q8W dosing over both the Q4W regimen and their previous daily oral regimen. The PRO data collected at Week 48 support the therapeutic potential of CAB + RPV LA.

Funding: ViiV Healthcare and Janssen.

Trial registration: ATLAS-2M: ClinicalTrials.gov NCT03299049, registered October 2, 2017.

Conflict of interest statement

VC, PDB, KYS, and WRS are employees of ViiV Healthcare and stockholders of GlaxoSmithKline. ETO has received research support to his institution during the conduct of this study and served as a consultant for Gilead, Merck, Thera Technologies, and ViiV Healthcare, outside of the submitted work. AM has received research funding and consulting fees from ViiV Healthcare, Gilead, Janssen, and Merck as well as consulting fees from Shionogi, all outside the submitted work. SS reports grants from ViiV Healthcare during the conduct of the study. SV and RVS are employees and stockholders of Janssen, Pharmaceutical Companies of Johnson & Johnson. YW is an employee and stockholder of GlaxoSmithKline. KJH was an employee of ViiV Healthcare and stockholder of GlaxoSmithKline during the conduct of the study and is now an employee of Horizon Therapeutics. MSS was an employee of ViiV Healthcare and stockholder of GlaxoSmithKline during the conduct of the study and is now an employee of Hengrui USA. DAM was an employee of ViiV Healthcare and stockholder of GlaxoSmithKline during the conduct of the study and is now an employee of Brii Biosciences.

© 2021. The Author(s).

Figures

Fig. 1

“Acceptance of ISRs” domain of the PIN questionnaire through Week 48a. CAB cabotegravir, ISR injection site reaction, LA long-acting, PIN Perception of Injection, Q4W every 4 weeks, Q8W every 8 weeks, RPV rilpivirine. aWeek 8: Q8W, n = 514; Q4W, n = 515; Week 24: Q8W, n = 515; Q4W, n = 515; Week 48: Q8W, n = 515; Q4W, n = 515

Fig. 2

Mean “Acceptance of ISRs” domain of the PIN questionnaire score through Week 48 for the total populationa (a) and participants with no prior CAB + RPV exposureb (b). CAB cabotegravir, ISR injection site reaction, LA long-acting, PIN Perception of Injection, Q4W every 4 weeks, Q8W every 8 weeks, RPV rilpivirine, SD standard deviation. aWeek 8: Q8W, n = 514; Q4W, n = 515; Week 24: Q8W, n = 515; Q4W, n = 515; Week 48: Q8W, n = 515; Q4W, n = 515. P values correspond to the Wilcoxon signed-rank test used to compare the Week 24 and Week 48 scores with the Week 8 scores. P values are derived for “acceptance” only and not adjusted for multiple testing. bWeek 8: Q8W, n = 320; Q4W, n = 321; Week 24: Q8W, n = 321; Q4W, n = 321; Week 48: Q8W, n = 321; Q4W, n = 321. P values correspond to the Wilcoxon signed-rank test used to compare the Week 24 and Week 48 scores with the Week 8 scores. P values are derived for “acceptance” only and not adjusted for multiple testing

Fig. 3

Adjusted mean change from baseline in “General Acceptance” score of the ACCEPT questionnaire by visit for participants without prior CAB + RPV exposure (a) and with prior CAB + RPV exposure (b)a. ACCEPT Chronic Treatment Acceptance Questionnaire, ANCOVA analysis of covariance, CAB cabotegravir, CI confidence interval, LA long-acting, Q4W every 4 weeks, Q8W every 8 weeks, RPV rilpivirine. aNo prior exposure, Week 24: Q8W, n = 319; Q4W, n = 323; Week 48: Q8W, n = 319; Q4W, n = 324; prior exposure, Week 24: Q8W, n = 192; Q4W, n = 194; Week 48: Q8W, n = 192; Q4W, n = 194. Adjusted mean change from baseline calculated from an ANCOVA model including the following covariates: baseline score, sex at birth (female, male), age (< 50, ≥ 50 years), and race (white, non-white) for participants with no prior exposure; baseline score, sex at birth (female, male), age (< 50, ≥ 50 years), race (white, non-white), and prior exposure to CAB + RPV (1–24, > 24 weeks) for participants with prior exposure

Fig. 4

Adjusted mean change from baseline in HIVTSQs by visit for participants without prior CAB + RPV exposure (a) and with prior CAB + RPV exposure (b)a. ANCOVA analysis of covariance, CAB cabotegravir, CI confidence interval, HIVTSQs HIV Treatment Satisfaction Questionnaire (status version), LA long-acting, Q4W every 4 weeks, Q8W every 8 weeks, RPV rilpivirine. aNo prior exposure, Week 24: Q8W, n = 319; Q4W, n = 323; Week 48: Q8W, n = 319; Q4W, n = 323; prior exposure, Week 24: Q8W, n = 191; Q4W, n = 193; Week 48: Q8W, n = 191; Q4W, n = 194. Adjusted mean change from baseline calculated from an ANCOVA model including the following covariates: baseline score, sex at birth (female, male), age (< 50, ≥ 50 years), and race (white, non-white) for participants with no prior exposure; baseline score, sex at birth (female, male), age (< 50, ≥ 50 years), race (white, non-white), and prior exposure to CAB + RPV (1–24, > 24 weeks) for participants with prior exposure

Fig. 5

Treatment preference at Week 48 in the Q8W arm (a) and Q4W arm (b). CAB cabotegravir, LA long-acting, Q4W every 4 weeks, Q8W every 8 weeks, RPV rilpivirine, SOC standard of care. a306 participants responded to the preference question. b191 participants responded to the preference question. c497 participants responded to the preference question. Figure 5a reprinted from The Lancet, Volume 396, Overton et al., Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study, Pages 1994–2005. Copyright (2020), with permission from Elsevier